Article

Wait time to nephrectomy does not affect recurrence

Waiting time to nephrectomy is not a predictor of the recurrence of renal cell carcinoma.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Study results affirm effectiveness of evolving prostate cancer therapies
4 experts in this video
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
1 expert is featured in this series.
BRCA Mutations in mHSPC: Impact on Therapy Selection
1 expert is featured in this series.
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Defining and Managing BCG-Unresponsive NMIBC
Considerations for patient follow-up after onabotA administration
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Related Content
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
May 14th 2025

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

Hannah Clarke
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
Long-term data point to durable efficacy of Optilume for urethral strictures
May 13th 2025

Long-term data point to durable efficacy of Optilume for urethral strictures

Hannah Clarke
The freedom from re-intervention rate was 71%.
© 2025 MJH Life Sciences

All rights reserved.